Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Issue title: Anesthetics and Alzheimer's Disease
Guest editors: Pravat K. Mandalx and Vincenzo Fodaley
Article type: Review Article
Authors: Finder, Verena H.; *
Affiliations: Division of Psychiatry Research and Psychogeriatric Medicine, University of Zurich, Zurich, Switzerland | [x] Neurospectroscopy and Neuroimaging Laboratory, National Brain Research Center, Manesar, Gurgaon, India | [y] Department of Neurosciences, Psychiatric and Anesthesiological Sciences, University of Messina, Policlinico G. Martino, Messina, Italy
Correspondence: [*] Correspondence to: Verena H. Finder, PhD, Division of Psychiatry Research and Psychogeriatric Medicine, University of Zurich, August Forel-Strasse 1, CH-8008 Zurich, Switzerland. Tel.: +41 44 634 88 78; Fax: +41 44 634 88 74; E-mail: [email protected].
Abstract: Alzheimer's disease (AD) is the most common form of dementia, which affects more than 35 million people worldwide with increasing tendency. Satisfying therapies and prevention are not available. Since the first description of the fatal progressive neurodegenerative disease in 1907, however, major findings on the molecular mechanisms have been reported. Current clinical trials target diverse aspects and principles of AD, such as the generation and aggregation of amyloid-β (Aβ). Extracellular amyloid plaques, predominantly consisting of Aβ, and intracellular neurofibrillar tangles, formed by hyperphosphorylated tau, are the major pathological hallmarks in the brain of AD patients. AD is consequently one of about 40 identified amyloidoses – protein misfolding diseases, which share as their main pathogenic mechanism the aberrant deposition of endogenous proteins as amyloid fibrils. This article aims principally to introduce AD and its identified key players, to summarize classic and recent publications on the complex molecular mechanisms underlying the disease, and to discuss challenges that need to be faced for the development of improved therapeutic strategies.
Keywords: Alzheimer's disease, amyloid-β, amyloid-β protein precursor, fibrils, protein misfolding, oligomers, neurotoxicity, tau
DOI: 10.3233/JAD-2010-100975
Journal: Journal of Alzheimer's Disease, vol. 22, no. s3, pp. S5-S19, 2010
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]